Mid-portion tendinopathy typically responds faster than insertional problems due to easier injection access and slightly better baseline vascularity
The patient must: Be age 18 or older Have eligible Medicare Part D coverage Be prescribed treatment specifically for weight reduction and maintenance Participate in ongoing nutrition and physical activity intervention Not have already received a GLP-1 through their Part D plan Not be seeking coverage for another Part D-coverable indication, such as type 2 diabetes, moderate-to-severe obstructive sleep apnea, MASH, or cardiovascular risk reduction The patient must also have met one of these criteria when GLP-1 therapy was originally started: BMI 35 BMI 30 plus HFpEF, uncontrolled hypertension despite 2 medications, or CKD stage 3a+ BMI 27 plus prediabetes, prior MI, prior stroke, or symptomatic peripheral artery disease Important: Eligibility is based on BMI at treatment initiation, not necessarily the patients current BMI
Heal, D., Gosden, J
products are made with the highest quality ingredients and manufactured according to current Good Manufacturing Practices (cGMP)
The phrase Research Use Only does not settle the position where the wider presentation points towards human use
If youre using it alongside energy, hormone, or skin treatments, its generally safe but combining therapies should be guided by your health history and treatment goals